ArticleCell host & microbe2015
Double trouble: HIV latency and CTL escape.
Article in Cell host & microbe, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Human immunodeficiency virus vaccines: Advances, challenges and future perspectives.World journal of virology · 2026Review
- Unique molecular signatures in rebound viruses from antiretroviral drug and CRISPR-treated HIV-1-infected humanized mice.Communications biology · 2025Article
- Rapamycin enhances CAR-T control of HIV replication and reservoir elimination in vivo.The Journal of clinical investigation · 2025Article
- Plasma Levels of Secreted Cytokines in Virologically Controlled HIV-Infected Aging Adult Individuals on Long-Term Antiretroviral Therapy.Viral immunology · 2024Article
- Broad Recognition of Circulating HIV-1 by HIV-1-Specific Cytotoxic T-Lymphocytes with Strong Ability to Suppress HIV-1 Replication.Journal of virology · 2019Article
- The inhibitor apoptosis protein antagonist Debio 1143 Is an attractive HIV-1 latency reversal candidate.PloS one · 2019Article
- Accumulation of follicular CD8+ T cells in pathogenic SIV infection.The Journal of clinical investigation · 2018Article
- In vivo activation of latent HIV with a synthetic bryostatin analog effects both latent cell "kick" and "kill" in strategy for virus eradication.PLoS pathogens · 2017Article
- Advancements in Developing Strategies for Sterilizing and Functional HIV Cures.BioMed research international · 2017Review
- HIV-1 Tat and Viral Latency: What We Can Learn from Naturally Occurring Sequence Variations.Frontiers in microbiology · 2017Review
- Recent Insights into the HIV/AIDS Pandemic.Microbial cell (Graz, Austria) · 2016Review
- Challenges and Opportunities for T-Cell-Mediated Strategies to Eliminate HIV Reservoirs.Frontiers in immunology · 2015Review
- Experimental Approaches for Eliminating Latent HIV.Forum on immunopathological diseases and therapeutics · 2015Article
Corrections and comments
- Comment on
Authors and funding
2 authors.
Funding
Abstract
HIV can enter a state of latency that allows it to persist for decades in antiretroviral drug-treated patients. In a recent Nature paper, Deng et al. (2015) show that this latent reservoir also contains a large number of cytotoxic T lymphocyte escape mutants, presenting another challenge to HIV cure efforts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.